Results 31 to 40 of about 27,201 (202)

Real‐world data of lapatinib and treatment after lapatinib in patients with previously treated HER2‐positive metastatic breast cancer: A multicenter, retrospective study

Cancer Medicine, 2020
Lapatinib is widely used in the later lines treatment of HER2 positive metastatic breast cancer (MBC). EGF104900 study suggested that among patients who experienced progression on prior trastuzumab‐containing regimens, lapatinib plus trastuzumab had ...
Yizhao Xie, Rui Ge, Die Sang, Ting Luo, Wei Li, Xuening Ji, Peng Yuan, Biyun Wang   +7 more
doaj   +1 more source

Neuroprotective Effects of the Anti-cancer Drug Lapatinib Against Epileptic Seizures via Suppressing Glutathione Peroxidase 4-Dependent Ferroptosis

Frontiers in Pharmacology, 2020
Epilepsy is a complex neurological disorder characterized by recurrent and unprovoked seizures. Neuronal death process is implicated in the development of repetitive epileptic seizures.
Ji-Ning Jia, Ji-Ning Jia, Ji-Ning Jia, Ji-Ning Jia, Xi-Xi Yin, Qin Li, Qin Li, Qin Li, Qin Li, Qi-Wen Guan, Qi-Wen Guan, Qi-Wen Guan, Qi-Wen Guan, Nan Yang, Nan Yang, Nan Yang, Nan Yang, Kang-Ni Chen, Kang-Ni Chen, Kang-Ni Chen, Kang-Ni Chen, Hong-Hao Zhou, Hong-Hao Zhou, Hong-Hao Zhou, Hong-Hao Zhou, Xiao-Yuan Mao, Xiao-Yuan Mao, Xiao-Yuan Mao, Xiao-Yuan Mao   +28 more
doaj   +1 more source

Characterisation and modulation of drug resistance in lung cancer cell lines [PDF]

, 2010
Chemotherapy drug resistance is a major obstacle in the treatment of cancer. It can result from an increase in levels of cellular drug efflux pumps such as P-glycoprotein (P-gp).
Dunne, Gráinne
core   +2 more sources

Gene expression changes as markers of early lapatinib response in a panel of breast cancer cell lines

Molecular Cancer, 2012
Background Lapatinib, a tyrosine kinase inhibitor of HER2 and EGFR and is approved, in combination with capecitabine, for the treatment of trastuzumab-refractory metastatic breast cancer.
O’Neill Fiona, Madden Stephen F, Aherne Sinead T, Clynes Martin, Crown John, Doolan Padraig, O’Connor Robert   +6 more
doaj   +1 more source

Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis

Systematic Reviews, 2022
Introduction Trastuzumab, as the gold standard for HER2-positive BC treatment, was the first-line HER2 targeted drug. However, some studies reported patients benefited more from lapatinib and lapatinib plus trastuzumab therapy than standard trastuzumab ...
Ye Yuan, Xumei Liu, Yi Cai, Wenyuan Li
doaj   +1 more source

The Possible Mechanism of Idiosyncratic Lapatinib-Induced Liver Injury in Patients Carrying Human Leukocyte Antigen-DRB1*07:01. [PDF]

PLoS ONE, 2015
Idiosyncratic lapatinib-induced liver injury has been reported to be associated with human leukocyte antigen (HLA)-DRB1*07:01. In order to investigate its mechanism, interaction of lapatinib with HLA-DRB1*07:01 and its ligand peptide derived from tetanus
Makoto Hirasawa, Katsunobu Hagihara, Noriko Okudaira, Takashi Izumi   +3 more
doaj   +1 more source

Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer.

PLoS ONE, 2015
We report here on experimental and theoretical efforts to determine how best to combine drugs that inhibit HER2 and AKT in HER2(+) breast cancers. We accomplished this by measuring cellular and molecular responses to lapatinib and the AKT inhibitors ...
James E Korkola, Eric A Collisson, Laura Heiser, Chris Oates, Nora Bayani, Sleiman Itani, Amanda Esch, Wallace Thompson, Obi L Griffith, Nicholas J Wang, Wen-Lin Kuo, Brian Cooper, Jessica Billig, Safiyyah Ziyad, Jenny L Hung, Lakshmi Jakkula, Heidi Feiler, Yiling Lu, Gordon B Mills, Paul T Spellman, Claire Tomlin, Sach Mukherjee, Joe W Gray   +22 more
doaj   +1 more source

Targeting PGK1 as a Novel strategy to regulate the sensitivity of HER2 positive gastric cancer to lapatinib

Frontiers in Pharmacology
HER2 is amplified in approximately 20% of gastric cancers, and these patients exhibit a favorable response to trastuzumab treatment. Lapatinib, as a HER2-targeted drug, demonstrates potent inhibitory effects on HER2-addicted N87 gastric cancer cells ...
Xiaochen Ni, Kaiyuan Zhang, Xueru Huang, Mingsi Zhang, Mingsi Zhang, Jianing Guo, Wei Fan, Chuhang Wang, Zhongyan Du, Zhongyan Du, Tao Jiang, Tao Jiang, Tao Jiang, Guangji Zhang, Guangji Zhang, Guangji Zhang   +15 more
doaj   +1 more source

Micro‐ and nanoplastics in gastrointestinal disorders: Mapping the translational gap between exposure, biomonitoring, and pathogenic mechanisms

BMEMat, EarlyView.
This review highlights critical “translational gaps” in understanding micro‐ and nanoplastics impacts on gastrointestinal diseases, bridging exposure, detecting, and mechanistic toxicology. Abstract Micro‐ and nanoplastics (MNPs) have become pervasive environmental contaminants with increasing evidence linking them to adverse health outcomes.
Zhenli Diao, Yujie Luo, Chuanda Zhu, Yanwei Hu   +3 more
wiley   +1 more source

The Effectiveness of Lapatinib in HER2-Positive Metastatic Breast Cancer Patients Pretreated With Multiline Anti-HER2 Treatment: A Retrospective Study in China

Technology in Cancer Research & Treatment, 2021
Background: The aim of this study was to evaluate the effectiveness of lapatinib in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer.
Xinzhao Wang MD, Lin Wang MD, Qian Yu PhD, Zhaoyun Liu MD, Chao Li MD, Fukai Wang MD, Zhiyong Yu MD, PhD   +6 more
doaj   +1 more source